COVID-19:宇部興産、アビガンの原薬供給:the active pharmaceutical ingredient (API)(動画):
COVID-19:Ube Industries to Begin Supplying Intermediates for Avigan® Tablet:
COVID-19:宇部工业开始提供Avigan®平板电脑的中间体
宇部興産株式会社:
2020年4月22日
宇部ケミカル工場:
宇部ケミカル工場(山口県宇部市)/医薬品工場で、「’アビガン®錠’( ファビピラビル)の原薬主骨格を成す重要な中間体」の製造及び供給を開始致します。
宇部興産は、グローバルに医薬品の原体・中間体製造を展開しています。
抗インフルエンザウイルス薬「アビガン」中間体の製造と供給実績を、有しています。
UBE INDUSTRIES,LTD.
https://www.ube-ind.co.jp/ube/jp/news/2020/20200422_01.html
Ube Industries to Begin Supplying Intermediates for Avigan® Tablet
TOKYO, April 22, 2020 —
Ube Industries, Ltd.
announced today that it will begin manufacturing and supplying the critical intermediates that constitute the active pharmaceutical ingredient (API) core skeleton for the influenza antiviral drug Avigan® Tablet (generic name: favipiravir), which was developed by FUJIFILM Toyama Chemical Co., Ltd.
Avigan
is expected to offer potential benefits for the treatment of coronavirus disease 2019 (COVID-19) amid a global pandemic.
The Japanese government
is fast-tracking clinical trials and approvals for Avigan while also supporting the establishment of a framework for manufacturing in Japan.
UBE INDUSTRIES,LTD.